Ophthalmology
3 drugs are in development for Retinitis Pigmentosa.
- Companies
- 2
- Clinical trials
- 13
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Retinitis Pigmentosa pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| ocu400 | Ocugen, Inc. (OCGN) |
Phase 1/Phase 2(2)
| Drug | Company |
|---|---|
| kio-301 | Kiora Pharmaceuticals Inc. (KPRX) |
| kio-301 | Kiora Pharmaceuticals Inc. (KPRX) |
About this indication
Retinitis Pigmentosa context
Ophthalmology·MeSH: Retinitis Pigmentosa (D012174)
Also known as: Pigmentary Retinopathies, Retinopathy, Pigmentary, Tapetoretinal Degeneration, Tapetoretinal Degenerations
Incidence
1.5 / 100K/yr
Frequently asked questions
How many drugs are in development for Retinitis Pigmentosa?
BioSniper tracks 3 drugs in development for Retinitis Pigmentosa across 2 companies.
How many clinical trials target Retinitis Pigmentosa?
There are 13 clinical trials targeting Retinitis Pigmentosa tracked by BioSniper.